Browsing Category
Pharma Industry News
4720 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Kardigan’s IPO demand looks strong, but the real test for KARD arrives in 2027
Kardigan raises $400 million in an upsized Nasdaq IPO to fund three cardiovascular trials. Discover the catalysts, cash runway and risks for KARD investors.
uniQure (QURE, NASDAQ) targets Q3 BLA after FDA’s Huntington’s reversal
The FDA spent months blocking uniQure's Huntington's gene therapy. Now it wants the filing in Q3. QURE doubled, but approval is still unwon.
Racura Oncology (ASX:RAC) funds three cancer trials, but can RC220 justify the valuation?
Racura Oncology has funded three RC220 trials, but valuation now depends on clinical proof. Can ASX:RAC turn capital into decisive cancer data?
Maiva Pharma expands sterile injectables capacity with Shoolagiri CDMO facility in Tamil Nadu
Maiva Pharma opens a Shoolagiri sterile injectables facility in Tamil Nadu. Find out how this CDMO expansion could reshape global supply.
Merck (MRK) signs $510m AI drug discovery deal with Protillion Biosciences
Merck (MRK) signs a $510 million AI drug discovery deal with Protillion Biosciences, expanding its AI push ahead of the Keytruda patent cliff. Full analysis.
J&J’s Talvey combination cuts the risk of death by up to 53% in earlier-line multiple myeloma
Johnson & Johnson (JNJ) Talvey combination cut the risk of death by up to 53% in earlier-line multiple myeloma, with FDA and EMA filings underway. Full analysis.
Why hereditary angioedema could become Intellia Therapeutics’ biggest CRISPR validation test
Find out how Intellia’s lonvo-z Phase 3 data could reshape HAE treatment and investor sentiment around in vivo CRISPR.
Why investors are watching Belite Bio after the tinlarebant NDA submission
Find out how Belite Bio’s tinlarebant FDA filing could reshape rare eye disease treatment and investor sentiment today.
What SL Bio’s Nasdaq debut reveals about biotech funding after the SPAC reset
Find out how SL Bio’s Nasdaq listing could shape SLBT stock, off-the-shelf cell therapy and biotech SPAC sentiment today!
Entropy Neurodynamics moves TRP-8803 into Cohort 2 as ASX:ENP awaits July data
Find out how Entropy Neurodynamics’ DSMB clearance for TRP-8803 could shape ASX:ENP’s next psychedelic medicine catalyst.